Cardiovascular diseases, including atrial fibrillation, coronary atherosclerotic heart disease, ischemic cardiomyopathy, ventricular tachycardia, etc.
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Case Group: (1) Age >18 years; (2) Definite diagnosis of heart disease [atrial fibrillation, coronary atherosclerotic heart disease, ischemic cardiomyopathy, ventricular tachycardia, etc.]; (3) Have undergone or agree to undergo ambulatory electrocardiogram (ECG) monitoring and sign the informed consent form; 2. Control Group: (1) Age > 18 years; (2) No history of heart disease; (3) Have undergone or agree to undergo ambulatory electrocardiogram (ECG) monitoring and sign the informed consent form;
Exclusion criteria
Exclusion criteria: 1. Case Group: (1) Severe valvular heart disease or congenital heart disease; (2) Presence of other severe systemic diseases that may affect fibrosis indicators: 1) Severe liver or kidney dysfunction; 2) Autoimmune diseases (e.g., systemic lupus erythematosus, rheumatoid arthritis); 3) Active malignant tumor; 4) Known systemic fibrotic disease (e.g., pulmonary fibrosis); (3) Inability to cooperate with PET/MR examination (e.g., claustrophobia, severe arrhythmia); (4) History of allergy to radiopharmaceuticals; 2. Control Group: (1) Symptoms or signs of heart disease; (2) ECG or other examinations suggesting possible heart disease; (3) Presence of other severe systemic diseases that may affect fibrosis indicators (same as above);
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Accuracy of PET-based fibrosis detection;Predictive capacity for disease recurrence or cardiovascular all-cause mortality; | — |
Countries
China
Contacts
The First Affiliated Hospital of Jinan University